Vedolizumab combined with surgical resection successfully treated perforating Crohn's disease with peritoneal space to rectal and vaginal fistulas: a case report.
Crohn’s disease
Fistula
Perforation
Surgery
Vedolizumab
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
29 Jul 2021
29 Jul 2021
Historique:
received:
20
04
2021
accepted:
06
07
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Intestinal perforations and fistulas are common complications of Crohn's disease. However, chronic perforation with peritoneal space to rectal and vaginal fistulas have not been previously reported. A 38-year-old female suffered from progressive lower abdominal pain, diarrhea and weight loss. Terminal ileal chronic perforation with intra-abdominal abscess, peritoneal space to rectal and vaginal fistulas were noted. The patient received surgical resection of the cecum and terminal ileum, and then vedolizumab treatment. Three months later, she had complete fistula closure, and her body mass index had increased from 13 to 22. Vedolizumab combined with stool diversion is effective at treating Crohn's disease with chronic perforation and complex peritoneal space to rectal and vaginal fistulas.
Sections du résumé
BACKGROUND
BACKGROUND
Intestinal perforations and fistulas are common complications of Crohn's disease. However, chronic perforation with peritoneal space to rectal and vaginal fistulas have not been previously reported.
CASE PRESENTATION
METHODS
A 38-year-old female suffered from progressive lower abdominal pain, diarrhea and weight loss. Terminal ileal chronic perforation with intra-abdominal abscess, peritoneal space to rectal and vaginal fistulas were noted. The patient received surgical resection of the cecum and terminal ileum, and then vedolizumab treatment. Three months later, she had complete fistula closure, and her body mass index had increased from 13 to 22.
CONCLUSION
CONCLUSIONS
Vedolizumab combined with stool diversion is effective at treating Crohn's disease with chronic perforation and complex peritoneal space to rectal and vaginal fistulas.
Identifiants
pubmed: 34325666
doi: 10.1186/s12876-021-01875-6
pii: 10.1186/s12876-021-01875-6
pmc: PMC8323229
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
vedolizumab
9RV78Q2002
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
299Informations de copyright
© 2021. The Author(s).
Références
Przegl Lek. 2011;68(9):602-5
pubmed: 22335009
Korean J Gastroenterol. 2009 Aug;54(2):108-16
pubmed: 19696538
J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):279-82
pubmed: 17255846
J Crohns Colitis. 2016 Feb;10(2):202-8
pubmed: 26512133
Clin Colon Rectal Surg. 2019 Jul;32(4):268-272
pubmed: 31275073
BioDrugs. 2010 Dec 14;24 Suppl 1:28-30
pubmed: 21175233
Am J Gastroenterol. 2004 Mar;99(3):445-9
pubmed: 15056083
Gastroenterology. 2010 Oct;139(4):1147-55
pubmed: 20637205
N Engl J Med. 1999 May 6;340(18):1398-405
pubmed: 10228190
J Crohns Colitis. 2018 Apr 27;12(5):621-626
pubmed: 29471381
Rev Esp Enferm Dig. 2013 Jan;105(1):3-6
pubmed: 23548004
Am J Gastroenterol. 2010 Feb;105(2):289-97
pubmed: 19861953
Inflamm Bowel Dis. 2018 Mar 19;24(4):752-765
pubmed: 29528400
Dig Dis. 2014;32 Suppl 1:103-9
pubmed: 25531361